bluebird to seek early approvals for blood disorder drug
This article was originally published in Scrip
Executive Summary
Shares of bluebird bio got a 9% boost on 19 May after the company revealed its plans to seek early approvals in the US and Europe to market its gene therapy LentiGlobin BB305 as a treatment beta-thalassemia major, a serious blood disorder.